Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genotype-phenotype correlation in PRKN-associated Parkinson's disease.

NPJ Parkinson's disease·2024
Same author

Two sample Mendelian Randomisation using an outcome from a multilevel model of disease progression.

European journal of epidemiology·2024
Same author

Addressing Comorbidities in People with Parkinson's Disease: Considerations From An Expert Panel.

Journal of Parkinson's disease·2024
Same author

Genome-wide Analysis of Motor Progression in Parkinson Disease.

Neurology. Genetics·2023
Same author

Identification of a possible proteomic biomarker in Parkinson's disease: discovery and replication in blood, brain and cerebrospinal fluid.

Brain communications·2023
Same author

The Impact of Type 2 Diabetes in Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2022

Related Experiment Video

Updated: Jun 23, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Dopamine agonists and therapy compliance.

Donald Grosset1

  • 1Department of Neurology, Southern General Hospital, Glasgow, G51 4TF, UK. d.grosset@clinmed.gla.ac.uk

Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|April 22, 2009
PubMed
Summary

Dopamine replacement therapy for Parkinson's disease can lead to Dopamine Dysregulation Syndrome (DDS), characterized by compulsive medication use and behavioral issues like pathological gambling. Strict adherence to medication is crucial for prevention.

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Related Experiment Videos

Last Updated: Jun 23, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Area of Science:

  • Neuroscience
  • Neurology
  • Psychiatry

Background:

  • Dopamine replacement therapy (DRT) is a cornerstone treatment for Parkinson's disease (PD) motor symptoms.
  • However, a subset of PD patients develop motor and behavioral complications from excessive medication.
  • Dopamine Dysregulation Syndrome (DDS) is a recognized complication of DRT.

Purpose of the Study:

  • To define Dopamine Dysregulation Syndrome (DDS) as a pattern of compulsive medication use in Parkinson's disease.
  • To explore the characteristics and potential causes of DDS, including its association with impulse control disorders.
  • To highlight the challenges in managing DDS and emphasize preventive strategies.

Main Methods:

  • This abstract discusses the clinical presentation and etiological considerations of DDS.
  • It reviews the literature on compulsive medication use and associated behavioral disturbances in Parkinson's disease patients.
  • The abstract focuses on the definition and clinical features of DDS, including pathological gambling.

Main Results:

  • DDS is characterized by compulsive use of dopaminergic medication beyond therapeutic needs for motor symptoms.
  • It is associated with overstimulation of the limbic dopaminergic system, leading to addiction and behavioral disorders.
  • Pathological gambling (PG), hypersexuality, punding, and mood swings are common manifestations of DDS.

Conclusions:

  • Dopamine Dysregulation Syndrome (DDS) presents a significant challenge in managing Parkinson's disease.
  • It is linked to addiction and impulse control disorders, notably pathological gambling.
  • Strict adherence to prescribed antiparkinsonian medication is essential for preventing DDS.